Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Adrenocortical Carcinoma 1Adrenal Gland Neoplasms 1

Interventions

Adrenalectomy 3Radiosurgery 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2pertuzumab 1olaparib 1lutetium Lu 177 dotatate 1iodophenyl metomidate 1camrelizumab 1apatinib 1X-Rays 1Radiofrequency Ablation 1Observation 1Nephrectomy 1N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride 1Mitotane 1Gefitinib 1Floxuridine 1Erlotinib Hydrochloride 1Dexamethasone 1Cystectomy 1Cryosurgery 1Adosterol 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adrenal Gland Neoplasms × iodophenyl metomidate × Clear all
NCT00454103 2010-08-18

Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy

University of Wuerzburg

Phase 1/2 Completed
Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡